Results 261 to 270 of about 1,208,067 (297)

LDL-cholesterol in newborns and children with genetically verified familial hypercholesterolaemia: implications for cholesterol-based screening. [PDF]

Eur Heart J
Bogsrud MP, Stava TT, Berge KE, Strøm TB, Retterstøl K, Holven KB.   +5 more
europepmc   +1 more source

Serum small dense LDL cholesterol is inversely associated with kidney stone prevalence: evidence from two independent cross-sectional studies. [PDF]

Front Endocrinol (Lausanne)
Zhang Y, Qin H, Yang J, Shen X, Hao Z, Liang C.   +5 more
europepmc   +1 more source

Adherence to the Mediterranean Diet and Its Association with LDL-Cholesterol and Subendocardial Viability Ratio in Individuals with Familial Hypercholesterolemia: A Cross-Sectional Study. [PDF]

Nutrients
Miano N, Scilletta S, Di Marco M, Capuccio S, Martedì M, Coppa M, Tincu N, Carasi S, Ippolito C, Pistritto C, Di Stefano C, Scarfia A, Pennisi C, Bosco G, Di Giacomo Barbagallo F, Di Pino A, Piro S, Scicali R.   +17 more
europepmc   +1 more source

LDL cholesterol and clinical outcomes in heart failure with reduced ejection fraction a competing risk analysis. [PDF]

Sci Rep
Wang Q, Liu Z, Zhou W, Wu G, Hu K, Su H, Yan J, Chen K.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment

Pathology, 2019
Low density lipoprotein (LDL) is the predominant atherogenic lipoprotein particle in the circulation. Conventionally, a fasting lipid profile has been used for atherosclerotic cardiovascular disease (ASCVD) risk assessment.
John R Burnett, Amanda Hooper, David Sullivan   +2 more
exaly   +2 more sources

What is ‘LDL cholesterol’?

Nature Reviews Cardiology, 2019
LDL cholesterol is an important contributor to the risk of coronary heart disease, and its measurement is central to evaluating the effects of lipid-modifying therapies.
M. Holmes, M. Ala-Korpela
semanticscholar   +2 more sources

Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years: a contemporary primary prevention cohort.

The Lancet, 2020
BACKGROUND Findings of historical studies suggest that elevated LDL cholesterol is not associated with increased risk of myocardial infarction and atherosclerotic cardiovascular disease in patients older than 70 years. We aimed to test this hypothesis in
M. Mortensen, B. Nordestgaard
semanticscholar   +1 more source

Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants.

The Lancet Diabetes and Endocrinology, 2020
BACKGROUND The benefits of LDL cholesterol-lowering treatment for the prevention of atherosclerotic cardiovascular disease are well established. However, the extent to which these effects differ by baseline LDL cholesterol, atherosclerotic cardiovascular
Nelson Wang, J. Fulcher, Nishan Abeysuriya, Laura Park, Shejil Kumar, G. D. Di Tanna, I. Wilcox, A. Keech, A. Rodgers, S. Lal   +9 more
semanticscholar   +1 more source